A Prospective Study of the BioFreedom™ Biolimus A9™ Drug Coated Stent in Patients at High Risk for Bleeding Study Details | NCT02843633 | LEADERS FREE II: BioFreedom™ Pivotal Study | ClinicalTrials.gov
Trancrocetins (TCs) have been reported to possess the capabilities to increase the diffusion of oxygen in plasma or water. Developed as a liposomal formulation of TC, LEAF-4L6715 allows for a gradual release of the free drug and was evaluated at multiple levels. A phase 1/2 trial including 37...
Multi-center, Open-label, Prospective, Randomized Study to Show Long-term Efficacy of DCB Treatment With Bail-out BRS in Comparison to BRS Treatment of De-novo Native Coronary Artery Lesions in a Relatively Young PCI Population. The goal of this study is to investigate the equivalence in early and...
LVAD Corheart6 is a single arm, prospective, open label and multicenter pre-market study. The objective is to to evaluate the safety and effectiveness of the Corheart 6 VAS when used for the treatment of advanced, refractory heart failure in an European population. The objective is to enroll 50...
MAGICAL SV is a prospective, multi-center, multinational, randomized, single-blind, pivotal, 2-arm parallel groups study. The objective is to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm) in patients with coronary artery disease. A...
MAnagement of High Bleeding Risk Patients Post Bioresorbable Polymer Coated STEnt Implantation With an Abb Reviated Versus Prolonged DAPT Regimen ClinicalTrials.gov ID: NCT03023020 The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in...
MENA TAVI is a single arm, prospective, open label and multicenter registry. The objective is to evaluate the ACURATE NEO 2 in the Middle East population suffering from severe symptomatic aortic stenosis. The objective is to enroll 100 patients from 6 investigational sites and patients will be...
Nagomi Complex PMCF is a Post-Market Clinical Follow-up Study with Ultimaster NagomiTM Sirolimus Eluting Coronary Stent System in Complex PCI Subjects 3,000 Complex subjects eligible for a percutaneous coronary intervention are enrolled in the study. Quantitative Coronary Angiography (QCA) will be...
OPTIXIENCE is an observational, international, multicentre and prospective study that aims to evaluate the clinical outcome of high-risk patients undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stent implantation using intracoronary tools for PCI guidance and optimization...
ClinicalTrials.gov ID: NCT03625869 PiCSO-AMI-I is a prospective, multicenter, randomized (1:1), controlled, study. Patients with an ST-segment elevated anterior infarct eligible for PCI will be invited to participate in the PiCSO-AMI-I study. After consent as per pproved ethics committee...
